Industry News
Pharmaceutical Industry News
Dr. Rana McKay speaks to the…
Dr. Rana McKay speaks to the ARANOTE trial of NUBEQA® (darolutamide) and what the data mean for patients, doctors, and care providers.
Huyabio has scored a win in the…
Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase inhibitor HBI-8000 has succeeded in combination with Bristol Myers Squibb’s Opdivo in a
AstraZeneca is shelling out up to…
AstraZeneca is shelling out up to $1.5 billion to lock down global rights to an EGFR lung cancer drug from Dizal Pharmaceutical, deepening its ties with a Chinese biotech it spun out nearly a decade
Real Chemistry has launched…
Real Chemistry has launched artificial intelligence tools for healthcare commercialization, continuing its embrace of technology tipped to transform biopharma marketing.
In the second of a new series of…
In the second of a new series of interviews with top executives from leading healthcare and comms agencies, Fierce Pharma Marketing sat down with London-based Havas SO’s managing director, Joanna Quade and Creative Director, Lucy
After speedrunning a series of…
After speedrunning a series of major manufacturing milestones in the past year-and-a-half, the “biotech floodgates” have opened for Cellares, the automated cell therapy manufacturing specialist’s co-founder and CEO told Fierce Pharma Manufacturing.
Insulet and Calm are integrating…
Insulet and Calm are integrating mental health care into diabetes treatment with a series of mindfulness, meditation and sleep tools specifically tailored to the diabetes community.
The FDA has proposed a streamlined…
The FDA has proposed a streamlined pathway for registering production facilities that operate under a “hub-and-spoke” model. The agency has also proposed clarifying the registration requirements for foreign manufacturers, especially those who make active pharmaceutical
Even as the effort has met with…
Even as the effort has met with fierce pushback, German lawmakers late Friday voted to pass health insurance reforms aiming at cutting healthcare costs, in part by hiking up mandatory rebates that pharmas must pay
In what GSK says represents a…
In what GSK says represents a potential way to transform treatment for patients with certain types of rectal cancer, the company’s Jemperli has met the main goal of a phase 2 trial, teeing up an
From resilient supply chains to…
From resilient supply chains to evolving modalities and AI-driven manufacturing, Samsung Biologics shares the forces transforming the CDMO landscape.
Lupin Pharmaceuticals, the U.S….
Lupin Pharmaceuticals, the U.S. unit of India’s Lupin Limited, issued a voluntary recall of more than 2.5 million bottles of prednisolone acetate ophthalmic suspension after an undisclosed contaminant was discovered.
Millions of Eye Drop Bottles Recalled Over Contamination Concerns
The prescription drops are used to reduce inflammation after surgery or to treat irritation.
The forever more popular…
The forever more popular combination of Padcev and Keytruda has expanded its bladder cancer territory once again.
The three-part video podcast…
The three-part video podcast series features Londyn, 15, and Connor, 20, who live with phenylketonuria, or PKU, as they discuss their daily lives and disease management.
Bayer has addressed its need for a…
Bayer has addressed its need for a capital infusion under a deal to secure 3 billion euros ($3.4 billion) in equity from New York City asset manager Apollo, surrendering a minority, non-controlling stake in its
The third time is not the charm…
The third time is not the charm for Hengrui Pharma and Elevar Therapeutics. The pair’s star-crossed cancer drug combination of camrelizumab and rivoceranib has been rejected by the FDA for the third time.
Sanofi has gained FDA approval of…
Sanofi has gained FDA approval of its subcutaneous version of Sarclisa, which can be delivered manually or by way of an on-body injector. The nod gives the multiple myeloma treatment a boost in its competition
AstraZeneca signed potential…
AstraZeneca signed potential billion-dollar licensing deals with CSPC and Sino Biopharm, Hengrui's Kaleira-partnered oral GLP-1 candidate reported obesity and diabetes phase 3 data from China, and biotech insiders decried certain U.S. lawmakers' scrutiny over Chinese
After several months of AbbVie…
After several months of AbbVie leading pharma’s monthly ad spend, Johnson & Johnson is back as Tremfya topped June’s rankings.